Current Report · Items 1.01, 3.02, 9.01 · 8-K
Palomino Laboratories Inc.
PALXOTCEQUITYCurrent
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. The information contained in Item 3.02 below relating to the various agreements described therein is incorporated herein by reference. All descriptions of the agreements described below are qualified in their entirety by reference to the form of the relevant agreement that is filed as an exhibit to this Report and incorporated herein by reference.
Filed Apr 24, 2026Accepted Apr 24, 2026, 5:15 PM EDTCIK 1938569Accession 0001493152-26-018963
Company context
Palomino is a fabless semiconductor company pioneering the next generation of high-performance microLED-based optoelectronic solutions for data communication. Its mission is to enable ultra-high-speed, energy-efficient optical interconnects that replace legacy copper-based PCIe and Ethernet links in compute-intensive environments. Palomino is commercializing a breakthrough platform built on advanced gallium nitride (GaN) compound semiconductor materials. This proprietary technology enables scalable and cost-efficient manufacturing of ultra-compact, high-speed optical transceivers, with significant improvements in power, size, and bandwidth density over traditional laser-based solutions. Palomino’s differentiated value proposition lies in leveraging high-efficiency microLEDs as optical sources in transceiver modules that can be seamlessly integrated into silicon packages or interposers. This approach unlocks the potential for high-density, chip-scale optical I/O—fundamentally reshaping the future of data movement in AI servers, data centers, and high-performance computing systems.
Current securities
Disclosure sections
Items 1.01, 3.02, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
ITEM
1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
The
information contained in Item 3.02 below relating to the various agreements described therein is incorporated herein by reference. All
descriptions of the agreements described below are qualified in their entirety by reference to the form of the relevant agreement that
is filed as an exhibit to this Report and incorporated herein by reference.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item
3.02 Unregistered Sale of Equity Securities.
The
Offering
On
April 20, 2026, Palomino Laboratories Inc. (the “ Company ”) entered into subscription agreements (each a “ Subscription
Agreement ”) with certain accredited investors and sold in an initial closing (the “ Initial Closing ”) of
a private placement (the “ Offering ”) an aggregate of 3,773,853 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the
“ Common Stock ”), for an aggregate purchase price of $15,095,412.00, at a purchase price of $4.00 per Share. The Company
and Laidlaw & Company (UK) Ltd. (the “ Placement Agent ”) may conduct additional closings until April 30, 2026 (together
with the Initial Closing, the “ Closings ”, and each a “ Closing ”) of the Offering at their discretion
for up to $30,000,000. Each investor in any closing subsequent to the date of the filing of this Report will be required to represent
that, as of the date of entering into the subscription agreement and the date of the applicable closing, it (i) has a substantive, pre-existing
relationship with us or has direct contact with us or the Placement Agent outside of the Offering, and (ii) did not independently contact
us or a Placement Agent or become interested in the Offering as a result of reading or otherwise being aware of this current Report,
any press release or any other public disclosure disclosing the terms of the Offering.
In
connection with the Offering, the Placement Agent will be paid at each Closing (i) a cash fee equal to ten percent (10%) of the gross
proceeds delivered to the Company on a closing date by parties introduced by the Placement Agent and (ii) five percent (5%) of the gross
proceeds delivered to the Company on a closing date by parties introduced by the Company, as well as a non-allocable expense reimbursement
equal to two (2%) of the gross proceeds delivered by Placement Agent introduced investors on a closing date to the Company, and one (1%)
of the gross proceeds delivered by Company introduced investors on a closing date to the Company. The Placement Agent will also receive,
at the final closing of the Offering, warrants to purchase shares of Common Stock in an amount equal to ten percent (10%) of the Common
Stock sold to Placement Agent introduced parties which are exercisable for five (5) years and have an exercise price equal to 120% of
the lowest price per share of the shares of Common Stock issued or issuable to investors in the Offering. The Company has agreed to pay
certain other expenses of the Placement Agent, including the fees and expenses of its counsel, in connection with the Offering. Subject
to certain customary exceptions, the Company will also indemnify the Placement Agent to the fullest extent permitted by law against certain
liabilities that may be incurred in connection with the Offering, including certain civil liabilities under the Securities Act of 1933,
and, where such indemnification is not available, to contribute to the payments the Placement Agent and its sub-agents may be required
to make in respect of such liabilities.
The
foregoing description of the Subscription Agreement does not purport to be complete and is qualified in its entirety by the full text
of the Subscription Agreement, a copy of which is attached hereto as Exhibit 4.1 and incorporated herein by reference.
Registration
Rights Agreement
In
connection with the Offering, the Company entered into a Registration Rights Agreement, by and among the Company and the purchasers of
Shares pursuant to the Offering (the “ Registration Rights Agreement ”). Under the terms of the Registration Rights
Agreement, the Company has agreed to file a resale registration statement on Form S-1 with the Securities and Exchange Commission
(the “ SEC ”) as soon as commercially reasonable, registering for resale the
Registrable Securities (as such term is defined in the Registration Rights Agreement). The Company will also use commercially reasonable
efforts to cause the registration statement to be declared effective no later than one hundred and twenty (120) days after the initial
filing date.
If
fewer than all of the Registrable Securities are included in the registration statement when it becomes effective, the Company will use
its commercially reasonable efforts within sixty (60) calendar days after the effective date of the registration statement, or as soon
as within thirty (30) business days after the first date that is permitted by the SEC, to register for resale as many of the Reduction
Securities (as defined in the Registration Rights Agreement) as the SEC will permit (pro rata among the holders of such Reduction Securities)
using one or more registration statements that it is then entitled to use, and to cause such registration statement(s) to become effective
as soon as practicable, until all of the Reduction Securities have been so registered; provided, however, that the Company shall not
be required to register such Reduction Securities during a Blackout Period (as defined in the Registration Rights Agreement).
The
holders of Registrable Securities shall have “piggyback” registration rights for Registrable Securities not registered as
provided above with respect to any registration statement filed by the Company following the effectiveness of the aforementioned registration
statement that would permit the inclusion of such underlying shares, subject, in an underwritten offering, to customary cut-back on a
pro rata basis among the holders of Registrable Shares if the underwriter or the Company determines that marketing factors require a
limitation on the number of shares of stock or other securities to be underwritten.
The
Company also entered into a registration rights agreement with the Placement Agent (the “ Laidlaw Registration Rights Agreement ”)
that provides for the registration of such holder’s Registrable Securities (as defined in the Laidlaw Registration Rights Agreement),
as and when the Company qualifies to file on Form S-3. The other terms of the Laidlaw Registration Rights Agreement are substantially
similar to the Registration Rights Agreement (together with the Registration Rights Agreement, “ Registration Rights Agreements ”).
The
foregoing description of the Registration Rights Agreements does not purport to be complete and is qualified in its entirety by the full
text of the Registration Rights Agreements, copies of which are attached hereto as Exhibit 10.1 and Exhibit 10.2 and are incorporated herein by reference.
Filed exhibits (1)
EX-4.1 (by filename) ex4-1.htmEX-4.1
2
ex4-1.htm
EX-4.1
Exhibit
4.1
EXECUTION
VERSION
SUBSCRIPTION
AGREEMENT
This
Subscription Agreement (this “ Agreement ”) has been entered into by and between the purchaser set forth on the
Omnibus Signature Page hereof (the “ Purchaser ”) and Palomino Laboratories Inc., a Delaware corporation
(the “ Company ”).
R
E C I T A L S
A.
The Company is offering a minimum of 3,750,000 shares of the Company’s common stock, par value $0.0001 per share (“ Common
Stock ”), at a purchase price of $4.00 per share (the “ Per Share Purchase Price ”), for an aggregate
purchase price of $15,000,000 (the “ Minimum Offering Amount ”), and a maximum of 7,500,000 shares of Common
Stock at the Per Share Purchase Price, for an aggregate purchase price of $30,000,000.
B.
The Placement Agent (as defined below) or its Affiliates or their respective officers, directors, shareholders or employees may (but
are not obligated to) also purchase Shares (as defined below) in the Offering (“ Placement Agent Investments ”),
and to the extent they do so, such purchases will be counted towards the achievement of the Minimum Offering Amount.
C.
None of the Shares (sometimes referred to herein as the “ Se…
Open exhibit ↗